This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Epratuzumab's B-Cell Modulation Effect Elucidated In Preclinical Study

-- Unique Mechanism of Action Involves Transfer of Key B-Cell Receptor Proteins From B Cells to Other White Blood Cells -- -- Study Presented at the 2012 Annual Meeting of the American Society of Hematology --

ATLANTA, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that its lead antibody drug candidate, epratuzumab, has a distinct way of reducing the immune response of B cells, which, in an autoimmune disease such as lupus, are responsible for producing antibodies that attack the patient's own body.

Epratuzumab is a humanized antibody targeting the CD22 receptor on B cells. Originally developed by the Company, the anti-CD22 antibody has previously demonstrated therapeutic activity in non-Hodgkin lymphoma (NHL) and systemic lupus erythematosus (SLE), and is currently in two Phase III clinical trials for the treatment of SLE (EMBODY 1 and EMBODY 2). Epratuzumab is being developed in SLE by UCB who hold the worldwide development rights for this compound in autoimmune diseases.The Company retains all rights in oncology.

While it is known that epratuzumab causes a reduction of about 45% of circulating B cells, in contrast to veltuzumab and other anti-CD20 antibodies that deplete more than 90% of B cells, the mechanism of action of epratuzumab in SLE remains to be fully understood.

Peripheral blood mononuclear cells (PBMCs) from normal donors, SLE patients, and of NHL cells spiked into normal PBMCs were used in this preclinical study. When bound to the CD22 receptor on B cells, epratuzumab promptly induced the transfer of key proteins associated with the B-cell receptor complex from B cells to other white blood cells such as monocytes, natural killer cells and granulocytes. In addition to CD22, receptors that were transferred include CD19, CD21 and CD79b. Interestingly, SLE patients currently on epratuzumab therapy showed significantly lower levels of CD22, CD19 and CD21, compared to treatment-naive patients.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,233.56 +76.71 0.45%
S&P 500 2,009.43 +7.86 0.39%
NASDAQ 4,586.1220 +23.9330 0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs